A randomized trial of bortezomib in late antibody-mediated kidney transplant rejection
F Eskandary, H Regele, L Baumann… - Journal of the …, 2018 - journals.lww.com
Late antibody-mediated rejection (ABMR) is a leading cause of kidney allograft failure.
Uncontrolled studies have suggested efficacy of the proteasome inhibitor bortezomib, but no
systematic trial has been undertaken to support its use in ABMR. In this randomized,
placebo-controlled trial (the Bortezomib in Late Antibody-Mediated Kidney Transplant
Rejection [BORTEJECT] Trial), we investigated whether two cycles of bortezomib (each
cycle: 1.3 mg/m 2 intravenously on days 1, 4, 8, and 11) prevent GFR decline by halting the …
Uncontrolled studies have suggested efficacy of the proteasome inhibitor bortezomib, but no
systematic trial has been undertaken to support its use in ABMR. In this randomized,
placebo-controlled trial (the Bortezomib in Late Antibody-Mediated Kidney Transplant
Rejection [BORTEJECT] Trial), we investigated whether two cycles of bortezomib (each
cycle: 1.3 mg/m 2 intravenously on days 1, 4, 8, and 11) prevent GFR decline by halting the …
以上显示的是最相近的搜索结果。 查看全部搜索结果